Risperidone Therapy

Risperidone Therapy is a pharmacotherapeutic intervention within the class of antipsychotic treatments that employs the atypical antipsychotic risperidone as its primary agent to modulate dopaminergic and serotonergic neurotransmission for the management of psychotic disorders.

3K

Publications

172.3K

Citations

10.5K

Authors

2.7K

Institutions

Publications per year

2017–2026

347

Authors

10.5K

  1. JM
    John M. Kane

    Zucker Hillside Hospital, United States

    41 publications · 3.5K citations

    32

    h-index

  2. SA
    Shahin Akhondzadeh

    Tehran University of Medical Sciences, Iran

    49 publications · 2.6K citations

    30

    h-index

  3. JA
    Jeffrey A. Lieberman

    Columbia University, United States

    32 publications · 7.3K citations

    29

    h-index

  4. ME
    Mariëlle Eerdekens

    Johnson & Johnson (United States), United States

    28 publications · 4.1K citations

    28

    h-index

  5. MG
    Michael G. Aman

    The Ohio State University, United States

    37 publications · 5.3K citations

    28

    h-index

1–5 of 10.5K

Venues

  1. The Journal of Clinical Psychiatry

    175 publications · 15.8K citations

    75

    h-index

  2. American Journal of Psychiatry

    85 publications · 18.7K citations

    68

    h-index

  3. Journal of Clinical Psychopharmacology

    122 publications · 9.1K citations

    52

    h-index

  4. PubMed

    Repository · 193 publications · 9.5K citations

    51

    h-index

  5. Journal of Child and Adolescent Psychopharmacology

    JCAP · 91 publications · 4.8K citations

    43

    h-index

1–5